Clinical comprehensive evaluation of four bisphosphonate drugs in osteoporosis
Objective To evaluate the effects and value of four commonly used bisphosphonate preparations in clinical practice in China from multiple dimensions,in order to lay a theoretical foundation for drug selection and disease treatment in medical institutions and provide data support.Methods Referring to the standardized content of the"Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions(Second Edition)",the effects and value of four different bisphosphonate preparations were discussed and evaluated at different levels such as pharmaceutical characteristics,effectiveness,safety and economical efficiency.Results The health technical scores of 4 kinds of bisphosphonate preparations were 79 points of alendronate sodium,71.07 points of risedronate sodium,75.77 points of ibandronate sodium and 66.42 points of zoledronic acid,all of which could be safely and effectively used in the treatment of osteoporosis.However,each of these drugs has its advantages and disadvantages,among which alendronate sodium has advantages in pharmaceutical properties,effectiveness and economy.Zoledronic acid has the worst safety and the best other properties.Ibandronate sodium has the highest safety.Conclusion Alendronate sodium has the highest comprehensive evaluation score,and the four bisphosphonate drugs have good efficacy in the treatment of postmenopausal women,adult men and glucocorticoid-induced osteoporosis.Ibandronate sodium has the most satisfactory safety performance.It can also be used in patients with abnormal liver and kidney function and the incidence of adverse reactions is relatively low.The result provides scientific basis for the selection of hospital drug list.
万方数据
维普
